Lyme disease (formerly Lyme arthritis) was recognized in November 1975 because of unusual geographic clustering of children with inflammatory arthropathy in the region of Lyme, Connecticut [1] . It is now known to be a complex immune-mediated multi-system disorder occurring at any age, in either sex, with onset in summer or early fall. Its clinical hallmark is an early expanding skin lesion, erythema chronicum migrans (ECM), which may be followed weeks to months later by neurologic, cardiac, or joint abnormalities [2] [3] [4] [5] [6] [7] . Symptoms may refer to any one of these four systems alone or in combination. Foci of Lyme disease have been found elsewhere along the northeastern coast of the United States, in many other states, in Europe, and in Australia. The disease is caused by a newly recognized spirochete [8] [9] [10] , and transmitted primarily by the minute tick Ixodes dammini or by related ixodid ticks [11-13J] .
Since our earliest work on Lyme disease, we have always looked beyond it, for possible insights into the onset and development of other inflammatory immunemediated, "rheumatic" diseases. Here we shall consider for comparison rheumatoid arthritis, the most prevalent example of this constellation of disorders. As a human model for an infectious etiology of rheumatic disease, Lyme disease has distinct advantages, of which some of the more important ones (Table 1) form the core of this discussion.
The seasonal onset, in summer or early fall, provided a synchronized patient population and allowed us to "tool up" for each new outbreak, for whatever study seemed most attractive at the time. The closeness of the Lyme region to our group in New Haven helped make effective a surveillance network. For the epidemiology of 473 In the study of Lyme disease, erythema chronicum migrans (ECM) has had many roles. It quickly became the most definitive diagnostic sign [2, 7] . From its appearance, and from patient histories, epidemiologic studies, and a long European experience with ECM, we were led backward rather quickly to the tick vector [11] [12] [13] , now called Ixodes dammini [14] , and eventually to the causative spirochete [8] [9] [10] . Most important for experimental work, erythema chronicum migrans marks the clinical onset of disease, the "zero time" so important for proper retrospective and especially prospective studies [15] .
Together with its establishment of clinical onset, erythema chronicum migrans marks a pre-articular phase of Lyme disease. This advantage manifested itself in several ways. It allowed a spectrum of clinical subgroups to be established. At one extreme were those with mild disease, consisting of erythema chronicum migrans that healed without sequelae. At the other extreme were patients with severe disease having subsequent neurologic or chronic joint involvement. We could therefore compare not only affected individuals with controls, but subgroups of patients with each other. Subgroups were found to differ in their humoral immune response [16, 17] : those with elevated serum IgM and cryoglobulins containing IgM at the time of ECM were likely to develop subsequent severe disease; those without these findings were not. In other words, the early humoral findings had prognostic significance.
In immunogenetic studies [4, 18] [7] . The afflicted joint may be pathologically indistinguishable from one affected by rheumatoid arthritis, even to the extent of pannus formation and erosion of cartilage and bone [2, 4, 6] . Thus, the model demonstrates that this final common pathway of joint pathology-this "rheumatoid" lesion-can occur within a matter of months.
The well-defined zero time and pi-e-articular phase also allowed us to trace the im- [22, 23] . The clear implication, since confirmed [9] , was that a penicillin-(and tetracycline)-sensitive agent is often still present at this stage of the illness.
This finding ruled out a viral etiology, and narrowed the possible contenders to a list on which some kind of spirochete was most likely. It also provided a general method of approaching the question whether the host is still harboring a live causative agent at a given stage of disease: if penicillin cures the disease, then the agent was there. (Note that only this positive result is decisive; failure to cure is more ambiguous.) And penicillin in particular can be used in high parenteral dosage with relative impunity. Indeed, we have now cured Lyme meningitis with penicillin [24] (and the causative agent has been cultured from cerebrospinal fluid [9] ). We are well aware of the rheumatologic implications of a disorder (Lyme meningitis) formerly treated with high-dose corticosteroids tapered over months [3] , now cured by highdose penicillin in days [22] . Formerly, we suppressed the host's response to an agent that is immunostimulatory but otherwise apparently rather unaggressive; now (with antibiotics) we address the agent directly.
We are currently evaluating the effect of high-dose penicillin on established Lyme arthritis. The question whether a persistent infectious agent is necessary for continued disease activity (versus the persistence of antigenic degradation products; the periodic rechallenge of ultimately injurious immunologic memory cells; or the trig-gering of true self-perpetuating autoimmunity) is of central importance in a number of immune-mediated disorders. ' The final major advantage of this model is its known causative agent, the L dammini spirochete. Specific antigen is what every rheumatologist dreams of having at his disposal; a whole organism is even better. It opens up entirely new areas of endeavor; for example, diagnosis through the use of specific antibody [8] [9] [10] ; localization of the organism [25, 27] (or parts of it, or cross-reacting components) in tissues; the antigen-specific immunology of the disease; the establishment of prevalence in vectors [8] [9] [10] , and of true attack rates in human and animal hosts; and the development of animal models.
In summary, as a model for an infectious etiology of rheumatic disease (Table 1) , Lyme disease, a human, immune-mediated inflammatory disorder, has intrinsic advantages which, taken together, are unique. We suspect that this model will continue to be useful in helping us to consider the possible evolution of other rheumatic problems whose developmental signposts are less prominent or lacking.
'Note added in proof: Since this paper was written, we have presented evidence that Lyme arthritis may be treated successfully with high-dose parenteral penicillin [26] . Moreover, spirochetes have been found in synovial lesions of Lyme arthritis [27] .
